

Press Release

Revenue up 14% to Rs. 1475 crores in Q2 FY23.

Vadodara, November 11th, 2022

Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter and half year ended 30th September, 2022.

Financial Highlights

- Net Sales for the quarter up 14% to Rs. 1475 crores.
- Net Profit for the quarter at Rs. 133 crores.
- Net sales for H-1 FY23 at Rs. 2737 crores.
- Net profit for H-1 FY23 at Rs. 67 crores.

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “It was a satisfactory quarter led by growth in all the verticals of the company, in particular the API business outperformed with a 23% growth during the quarter”

Operational Highlights

India Formulations Business

- India Formulations Business grew at 11% (Excluding one time non recurring sales of Amphotericin – B) to Rs. 549 crores in the quarter.
- India Growth for the quarter is on back of exceptionally high market growth in Q2 FY 21-22. Alembic clocked a large out-performance vs market.
- Specialty segment grew faster than the market.

International Business

- US Generics grew 20% to Rs. 418 crores in the quarter.
- Ex-US International Formulations grew 9% to Rs. 215 Crores in the quarter.
- 3 ANDA approvals received during the quarter; 170 Cumulative ANDA approvals.
- 5 ANDA filings during the quarter; Cumulative ANDA filings at 242.

API Business

- API business grew 23% at Rs. 294 crores in the quarter.
- 126 cumulative DMF Filings.



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

The summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q2 FY23	Q2 FY22	% Change	H-1 FY23	H-1 FY22	% Change
Formulation						
USA	418	348	20%	785	716	10%
Ex- US	215	197	9%	396	394	1%
India	549	509	8%	1029	989	4%
API	294	239	23%	527	519	2%
Total	1475	1292	14%	2737	2618	5%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 4700 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai Phone: +91 22 – 306 11681 Email: ajay.desai@alembic.co.in	Mitanshu Shah Phone: +91 265 – 6637630 Email: mitanshu.shah@alembic.co.in
---	---



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123